Plain-English translation of NCT07283835 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called Cretostimogene, which is designed to help your immune system fight bladder cancer that hasn't responded to the standard BCG treatment. The medication is given directly into your bladder through a catheter, rather than by pill or injection into your bloodstream. This approach allows the treatment to work where the cancer is located.
Many patients with high-risk bladder cancer don't respond well enough to BCG therapy, which is the current standard treatment. Doctors need new options for these patients to help them avoid having their entire bladder removed, which is a major surgery that significantly affects quality of life.
You likely qualify if…
You likely don't qualify if…
You will receive the medication through a catheter placed in your bladder on a weekly schedule. Before each treatment, your bladder will be washed with a special solution to prepare it. You will need to hold the medication in your bladder for about an hour before emptying it. Throughout the study, you'll return for regular office cystoscopies (camera exams of your bladder), urine tests, imaging scans, and biopsies to monitor how you're responding to the treatment.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China